HLA-V: A Target for Drug and Biomarker Development (G352962)

Target Name: HLA-V

NCBI ID: G352962

HLA-V

HLA-V: A Target for Drug and Biomarker Development

The Major Histocompatibility Complex (MHC) is a critical immune system protein that plays a vital role in the immune response. MHC class I is a subclass of MHC that is expressed in most tissues and cells, including the skin, hair, nails, and nervous system. MHC class I molecules are involved in the presentation of antigens to T-cells, which are then responsible for cell-mediated immunity.

HLA-V is a specific subclass of MHC class I that is expressed in a subset of tissues and cells. HLA-V is a 14 kDa protein that is composed of two heavy chains and two light chains. The heavy chains contain the major functional regions of MHC class I molecules, including the alpha and beta chains. The light chains contain the variable and constant regions of MHC class I molecules.

HLA-V is involved in the presentation of antigens to CD8+ T-cells, which are a crucial part of the immune response. CD8+ T-cells are known for their ability to recognize and destroy infected or mutated cells, and are an important part of the immune response to viruses, tumors, and other intracellular pathogens.

Despite its involvement in the immune response, HLA-V has also been shown to have important roles in development and regulation. For example, HLA-V has been shown to play a role in the development of autoimmune diseases, such as rheumatoid arthritis and lupus. HLA-V has also been shown to be involved in the regulation of T-cell development and function, including T-cell receptor (TCR) selection and clonal expansion.

As a result of its involvement in the immune response and development, HLA-V has become an attractive target for drug development. Researchers have been exploring the use of small molecules and antibodies to modulate HLA-V activity and improve the immune response. One approach is to use small molecules that can bind to specific HLA-V regions to modulate its activity. This approach has been shown to be effective in animal models of autoimmune diseases.

Another approach to modulating HLA-V activity is to use antibodies that can specifically recognize and block HLA-V in the immune system. This approach has been shown to be effective in animal models of autoimmune diseases and has the potential to be a useful treatment for these diseases.

In addition to its potential as a drug target, HLA-V is also an important biomarker for autoimmune diseases. The HLA-V gene is often expressed in higher levels in individuals with autoimmune diseases, and changes in HLA-V expression have been observed in these individuals. For example, research has shown that individuals with rheumatoid arthritis (RA) have lower levels of HLA-V compared to individuals without RA.

Overall, HLA-V is an important protein that is involved in the immune response and development. Its role in these processes makes it an attractive target for drug development and research into the underlying mechanisms of autoimmune diseases. Further research is needed to fully understand the functions of HLA-V and its potential as a drug and biomarker.

Protein Name: Major Histocompatibility Complex, Class I, V (pseudogene)

The "HLA-V Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-V comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets